Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors Reply
- 浏览0
Journal of Clinical Oncology
1840-1841页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



